Verge Genomics

vergegenomics.com

Verge Genomics is pioneering an AI-powered drug discovery platform that utilizes human genomics and machine learning to develop proprietary drug candidates for neurodegenerative diseases. Their first drug, VRG50635, targets amyotrophic lateral sclerosis (ALS) and has progressed to clinical trials within four years. The company is focused on addressing significant medical challenges, including Parkinson's Disease and Frontotemporal Dementia, leveraging a unique multi-omics database derived from human tissue. Verge's innovative approach and collaboration with industry leaders position it as a transformative player in the biotechnology sector, aiming to deliver better drugs faster.